Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to misleading statements about Medicaid cost trends and financial guidance [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including Medicaid benefits, and was under scrutiny for its handling of Medicaid eligibility redeterminations that resumed in 2023 after a pause during COVID [3]. - The company claimed to be monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Financial Impact and Stock Performance - Allegations suggest that the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following a statement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit involves claims that Elevance and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance and Market Reaction - On July 17, 2024, Elevance's CEO reported a shift in Medicaid membership mix leading to increased acuity, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [4]. - During the October 17, 2024, earnings call, the CEO disclosed that adjusted diluted earnings per share for the third quarter were $8.37, below expectations due to elevated medical costs in Medicaid, causing a stock price decline of $52.61 per share, or 10.6%, closing at $444.35 [5]. - The full-year outlook for adjusted diluted earnings per share was reduced from $37.20 to approximately $33, despite previous guidance just three months earlier [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for allegedly misleading investors regarding the company's Medicaid cost trends and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Group 1: Allegations and Misrepresentation - The lawsuit claims that Elevance's management assured investors that they were monitoring Medicaid cost trends and that premium rates were sufficient to manage risks associated with Medicaid patients [2]. - It is alleged that while management acknowledged rising Medicaid expenses, they misrepresented that these were adequately reflected in the company's financial guidance for 2024 [2]. - The complaint states that management claimed to have "visibility into 75% of our Medicaid rates and premiums for 2024," asserting that the majority were actuarially sound, which is now disputed [2]. Group 2: Impact of Disclosures - The truth about rising acuity and utilization among Medicaid members began to emerge on July 17, 2024, when Elevance indicated an expectation of increased utilization in the second half of the year [3]. - Following this disclosure, Elevance's stock price fell by $32.21 per share, a decline of 5.8%, from $553.14 on July 16, 2024, to $520.93 on July 17, 2024 [3]. Group 3: Investor Actions - Investors who acquired shares of Elevance during the Class Period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on July 11, 2025 [4].

Core Insights - The article emphasizes the appeal of high-quality dividend growth stocks as a source of passive income, regardless of economic conditions or political views [1] - The author advocates for a disciplined investment strategy focused on long-term holdings of quality companies at reasonable valuations [1] Group 1: Investment Philosophy - The investment approach is characterized by prudent living, working, and investing, aiming for a sustainable lifestyle and career progression [1] - Dividend growth investing is highlighted as a suitable strategy for generating passive income and weathering market volatility [1] Group 2: Investment Strategy - Automatic dividend reinvestment is mentioned as a method to dollar-cost average and benefit from compounding growth [1] - The author expresses confidence in identifying high-quality companies that can be held long-term, contributing to financial stability [1]

Group 1 - FerdiS focuses on investing in dividend growth stocks and utilizes options to enhance dividend income [1] - The portfolio, DivGro, primarily consists of dividend growth stocks and was established in January 2013 [1] - FerdiS has over 20 years of investment and trading experience, contributing to articles on various investment topics [1] Group 2 - Collaboration with the founders of Portfolio Insight, which is an online platform for portfolio management and investment analysis [1] - Maintenance and publication of Dividend Radar, a weekly free spreadsheet that lists dividend growth stocks [1]

Core Viewpoint - The Ensign Group, Inc. (ENSG) reported strong first-quarter 2025 results, with increased occupancy rates and patient days contributing to revenue growth, although rising expenses partially offset the gains [1][2][3]. Financial Performance - Adjusted earnings per share (EPS) for Q1 2025 were $1.52, exceeding the Zacks Consensus Estimate by 1.3% and reflecting a year-over-year increase of 16.9% [2]. - Operating revenues reached $1.2 billion, marking a 16.1% year-over-year growth and beating the consensus estimate by 0.2% [2]. - Adjusted net income improved 18% year over year to $89 million, surpassing the estimate of $88.3 million [3]. Segment Performance - Skilled Services segment revenues grew 15.9% year over year to $1.12 billion, slightly missing the Zacks Consensus Estimate but exceeding internal estimates [4]. - Rental revenues from the Standard Bearer segment totaled $28.4 million, up 27.9% year over year, driven by buyouts [5]. Operational Metrics - Same-facilities occupancy improved by 230 basis points, while transitioning-facilities occupancy expanded by 400 basis points year over year [3]. - Total expenses increased by 15.5% year over year to $1.07 billion, higher than the estimate of $1.06 billion [3]. Cash and Debt Position - As of March 31, 2025, cash and cash equivalents were $282.7 million, down 39.2% from the end of 2024 [6]. - Long-term debt (less current maturities) was $140.6 million, a decrease of 0.7% from December 31, 2024 [7]. Capital Deployment - The company repurchased shares worth $10.8 million and paid dividends totaling $3.6 million in Q1 2025 [9]. 2025 Outlook - Revenue guidance for 2025 has been revised to a range of $4.89-$4.94 billion, indicating a 15.4% improvement from 2024 [10]. - Adjusted EPS is forecasted between $6.22 and $6.38 for 2025, reflecting a 14.5% growth from the previous year [10].

Core Viewpoint - Kroger is positioned as a resilient stock that can thrive in various economic conditions, making it a strong investment choice in both stable and turbulent markets [2][10]. Company Performance - In Q4 2024, Kroger reported an earnings per share (EPS) of $1.14, exceeding estimates by 3 cents, while revenues decreased by 7.4% year-over-year to $34.31 billion [4]. - For the full year 2024, Kroger achieved an EPS of $3.67 and an operating profit of $3.8 billion on total revenue of $147 billion [5]. - The company increased its gross margin by 250 basis points to 22.3%, marking a 38% increase over the past seven years [5]. Market Position - Kroger operates over 2,700 stores across 35 states and Washington, D.C., under various banners, ensuring a steady demand for groceries regardless of market conditions [3]. - The company competes with major grocery operators like Walmart, Target, and Albertsons [2]. Strategic Initiatives - Kroger's private label segment, "Our Brands," generated $30 billion, accounting for 20% of total revenue in 2024, and offers products with higher margins compared to national brands [7][8]. - The company has initiated a $5 billion accelerated share repurchase program, part of a larger $7.5 billion share repurchase authorization [5]. Economic Resilience - Kroger's business model allows it to thrive during inflationary periods by expanding its private label offerings, which provide wider margins and cater to budget-conscious consumers [6][7]. - During recessionary times, Kroger benefits as consumers shift from dining out to cooking at home, leading to increased sales [6]. Stock Performance - Kroger's stock reached a new 52-week high in April 2025, demonstrating its resilience compared to benchmark indexes like the S&P 500 and Nasdaq-100 [10]. - The stock has maintained a bullish Golden Cross since February 2024, contrasting with the performance of benchmark indexes [11].

Financial Data and Key Metrics Changes - GAAP diluted earnings per share was $9.61 and adjusted diluted earnings per share was $11.97, reflecting year-over-year growth of more than 10% [18] - Operating revenue in the quarter was $48.8 billion, an increase of over 15%, driven by higher premium yields in the Health Benefits segment and growth in Medicare Advantage and individual ACA membership [19] - The consolidated benefit expense ratio was 86.4%, an increase of 80 basis points year-over-year, primarily due to higher cost trends in the Medicaid business [20] Business Line Data and Key Metrics Changes - Health Benefits operating gain was $2.2 billion, slightly declining due to higher Medicaid costs, partially offset by operating efficiencies [20] - Calon's operating gain grew 34% to $1.1 billion, driven by growth in pharmacy volumes and improved performance of deployed risk-based capabilities [21] - The company ended the quarter with 45.8 million medical members, up 99,000 from year-end, primarily driven by targeted expansion and better-than-expected retention rates in Medicare Advantage [18] Market Data and Key Metrics Changes - Individual ACA membership grew approximately 11% sequentially, but a moderation in membership is anticipated during the second quarter due to lower-than-expected effectuation rates [18] - In Medicaid, progress on rate alignment is ongoing, with April adjustments coming in as expected and discussions for the July cohort underway [12] - The company is expanding its value-based oncology care model to Medicare Advantage, following success in the commercial segment [10] Company Strategy and Development Direction - The company is focused on advancing its purpose to improve the health of humanity through investments in patient advocacy solutions and digital platforms [7][9] - Elevance Health is expanding its integrated offerings, which combine advocacy, behavioral health, pharmacy, and specialty care, to enhance employer engagement [14] - The acquisition of CareBridge strengthens the company's capabilities in home and community-based services, supporting its whole health approach [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for Medicare Advantage, citing strong retention and disciplined growth strategies [13] - The company is monitoring trends closely, particularly in Medicare costs, which remain elevated but manageable [28] - Management reiterated guidance for adjusted diluted earnings per share to be in the range of $34.15 to $34.85, with expectations for more than 60% of earnings to be realized in the first half of the year [24] Other Important Information - The company was recognized as one of Fortune's 100 best companies to work for and included in the Just 100 by Just Capital, reflecting its commitment to values and impact [17] - The debt to capital ratio was approximately 41%, preserving flexibility for strategic investments [21] Q&A Session Summary Question: Medicare Advantage trends and IRA impact - Management indicated that Medicare costs remain elevated but manageable, with no material changes to prior expectations [27][28] Question: Growth in Carillon services and cross-sales - Carillon services experienced over 60% growth, with strong internal and external expansion noted [35][36] Question: Effectuation rates and membership expectations - Effectuation rates are tracking lower than initial expectations, with projected membership attrition in the mid-single-digit percent range in early Q2 [42] Question: Medicaid MLR margin trends - Medicaid trends remain elevated but decelerated as expected, with stabilization anticipated in the latter half of the year [92] Question: Part D utilization and new normal - Management is comfortable with the mix of Medicare Advantage membership and has not observed substantial variation in Part D utilization [112]

Financial Data and Key Metrics Changes - In Q1 2025, GAAP diluted earnings per share was $9.61, and adjusted diluted earnings per share was $11.97, reflecting year-over-year growth of more than 10% [25] - Operating revenue for the quarter was $48.8 billion, an increase of over 15%, driven by higher premium yields in the health benefits segment and growth in Medicare Advantage and individual ACA membership [26] - The consolidated benefit expense ratio was 86.4%, an increase of 80 basis points year over year, primarily due to higher cost trends in the Medicaid business [27] Business Line Data and Key Metrics Changes - Medicaid membership is progressing with rate alignment, and the long-term care model is delivering better outcomes at lower costs [16][17] - Medicare Advantage performance was consistent with expectations, with strong retention and disciplined growth [17] - The health benefits operating gain was $2.2 billion, slightly declining due to higher Medicaid costs, while Calon's operating gain grew 34% to $1.1 billion [29] Market Data and Key Metrics Changes - Individual ACA membership grew approximately 11% sequentially, but a moderation in membership is anticipated in Q2 due to lower effectuation rates [25][56] - The company is expanding into three new states to build lifetime value through coordinated ACA and Medicaid coverage [19] Company Strategy and Development Direction - The company is focused on transforming healthcare experiences to be simpler, more affordable, and more human, with sustained investments in patient advocacy solutions and digital platforms [9][10] - Elevance Health is expanding its value-based oncology care model to Medicare Advantage, following success in the commercial sector [12] - The company aims to deepen collaboration with providers and close gaps in care through risk-based arrangements, which have driven nearly $100 in per member per month savings [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for Medicare Advantage, emphasizing strong retention and targeted growth [17] - The operating environment remains elevated, but the company is managing costs effectively and expects to see stabilization in Medicaid margins later in the year [117] - Management reiterated guidance for adjusted diluted earnings per share to be in the range of $34.15 to $34.85 [33] Other Important Information - Elevance Health was recognized as one of Fortune's 100 Best Companies to Work For and included in the Just 100 by Just Capital, reflecting its commitment to values and impact [22] - The company repurchased 2.2 million shares of common stock for approximately $880 million, demonstrating confidence in its intrinsic value [33] Q&A Session Summary Question: Concerns regarding Medicare Advantage trends - Management indicated that Medicare costs remain elevated but manageable, with no material changes in expectations [39][41] Question: Growth in Carillon Services - Carillon Services experienced over 60% growth, with strong internal and external expansion [47] Question: Effectuation rates and membership attrition - Membership attrition is projected in the mid-single digit percent range in early Q2, with expectations for stabilization thereafter [57] Question: Medicaid MLR margin trends - Medicaid trends remain elevated but decelerated as expected, with improvements anticipated in the latter half of the year [117] Question: Part D and IRA impact - Changes from the Inflation Reduction Act are expected to shift the seasonality pattern for Part D, resulting in stronger financial performance in earlier quarters [68][70] Question: New member engagement strategy - The company is focused on early engagement with new members to ensure timely care and accurate health assessments [93] Question: Group MA trends - Utilization patterns for Group MA do not indicate any meaningful acceleration in cost trends compared to expectations [133]